Intensity Therapeutics (INTS) Stock Price, News & Analysis

Company Overview

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Key Stats

• Today's Range: $2.36 to $2.79
• 50-Day Range: N/A
• 52-Week Range: $0.26 to $5.10
• Volume: 73,559 shs
• Average Volume: 342,543 shs
• Market Capitalization: $7.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Moderate Buy

Intensity Therapeutics Stock Analysis - MarketRank™

Intensity Therapeutics scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Intensity Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Intensity Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Intensity Therapeutics are expected to grow in the coming year, from ($1.18) to ($1.00) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Intensity Therapeutics is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Intensity Therapeutics is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Intensity Therapeutics has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.58% of the float of Intensity Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Intensity Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Intensity Therapeutics has recently increased by 42.89%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Intensity Therapeutics does not currently pay a dividend.

Dividend Growth

Intensity Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.58% of the float of Intensity Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Intensity Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Intensity Therapeutics has recently increased by 42.89%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: 1.89

News Coverage This Week

MarketBeat has tracked 3 news articles for Intensity Therapeutics this week, compared to 0 articles on an average week.

Search Interest

6 people have searched for INTS on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Intensity Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.10% of the stock of Intensity Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 3.74% of the stock of Intensity Therapeutics is held by institutions.

INTS Stock Analysis - Frequently Asked Questions

How were Intensity Therapeutics' earnings last quarter?

Intensity Therapeutics Inc. (NASDAQ:INTS) posted its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.01.

When did Intensity Therapeutics IPO?

Intensity Therapeutics (INTS) raised $20 million in an initial public offering on Friday, June 30th 2023. The company issued 3,900,000 shares at a price of $5.00 per share.

What other stocks do shareholders of Intensity Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Intensity Therapeutics investors own include Amgen (AMGN), Costco Wholesale (COST), Cisco Systems (CSCO), Honeywell International (HON), Intel (INTC), Intuitive Surgical (ISRG) and Mondelez International (MDLZ).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED-BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: NASDAQ:INTS
• CIK: 1567264
• Web: www.intensitytherapeutics.com
• Phone: 203 221 7381
• Fax: N/A
• Employees: 2,021
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.50
• High Stock Price Target: $12.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +2,742.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.27 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -527.85%
• Return on Assets: -276.29%

Debt

• Debt-to-Equity Ratio: 0.31
• Current Ratio: 0.63
• Quick Ratio: 0.63

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.19 per share
• Price / Book: 1.57

Miscellaneous

• Outstanding Shares: 25,070,000
• Free Float: 20,786,000
• Market Cap: $7.50 million
• Optionable: Not Optionable
• Beta: 3.27